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Mucormycosis (MCM) is a life-threatening infection that carries high mortality rates despite recent advances in its diagnosis and
treatment. The objective was to report 14 cases of mucormycosis infection and review the relevant literature. We retrospectively
analyzed the demographic and clinical data of 14 consecutive patients that presented withMCM in a tertiary-care teaching hospital
in northern Mexico. The mean age of the patients was 39.9 (range 5–65). Nine of the patients were male. Ten patients had diabetes
mellitus as the underlying disease, and 6 patients had a hematological malignancy (acute leukemia). Of the diabetic patients, 3 had
chronic renal failure and 4 presented with diabetic ketoacidosis. All patients had rhinocerebral involvement. In-hospital mortality
was 50%. All patients receivedmedical therapy with polyene antifungals and 11 patients underwent surgical therapy. Survivors were
significantly younger and less likely to have diabetes than nonsurvivors, and had higher levels of serum albumin on admission.The
clinical outcome of patients with MCM is poor. Uncontrolled diabetes and age are negative prognostic factors.
1. Introduction
Mucormycosis (MCM) is a devastating infection with high
mortality rates despite recent advances in its diagnosis and
treatment. It is caused by the filamentous fungi of the
Mucorales order of the class of Zygomycetes [1]. Although
it is classically defined as an opportunistic infection, pref-
erentially affecting patients with diabetes mellitus (DM),
neutropenia, malignancy, chronic renal failure, and acquired
immunodeficiency syndrome and those who have received
organ or hematopoietic stem cell transplants, it can affect
immunocompetent hosts as well (such as trauma patients)
[1, 2]. The incidence of MCM worldwide appears to be
increasing, particularly in oncological patients and thosewith
DM [3]. Along with aspergillus, it is one of themost common
invasive fungal infections affecting immunosuppressed indi-
viduals.
Despite aggressive surgical and polyene antifungal ther-
apy, overall mortality for MCM infection remains high, with
figures ranging from 20 to 50% [4–6]. Depending on patient
characteristics (such as critically ill or immunocompromised
patients) and site of infection, mortality rises markedly,
nearing 70–90% for cases of disseminated mucormycosis
[4–6]. Inhalation of sporangiospores is the most common
route of transmission, although ingestion of spores, direct
implantation into injured skin (burns), trauma with contam-
inated soil, or intravenous (drug users) transmission have
also been described [7]. After nasal inoculation it takes a
rapidly progressive course extending to neighboring tissues,
including the orbit, and sometimes to the brain. Lipid for-
mulations of amphotericin B are the mainstay of treatment,
along with aggressive surgical therapy [8]. However, such
drug formulations are not available worldwide due to their
elevated costs.
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Most of the information on the epidemiology and clinical
characteristics of MCM comes from case series and small
studies on specific populations, such as those in oncology
centers. Considering the high mortality associated with
MCM and the increasing recognition of the importance
of this disease in Latin American countries, we set out
to describe the demographic and clinical characteristics of
MCM patients in a tertiary-care teaching hospital in Mexico.
2. Materials and Methods
2.1. Patients. Wereceived approval from the ethics committee
of our institution to carry out this study. From 2007 to
2012, we identified all patients with MCM at the University
Hospital “Jose Eleuterio Gonzalez,” and their records were
obtained to analyze the cases retrospectively. Demographic
characteristics, presentation, signs, and symptoms as well as
treatment and outcomes were analyzed. Cases were sought
through manual and electronic searches in hospital records
(using discharge diagnoses). All patients had been hospital-
ized (none came from outpatient clinics).
2.2. MCM Diagnostic Criteria. We used the 2008 European
Organization for Research and Treatment of Cancer/Mycoses
Study Group (EORTC/MSG) criteria for the diagnosis of
MCM [9], but only proven cases were retained. All cases
had expert histopathological confirmation and were culture
positive. Samples were most commonly obtained from the
sinus cavities.
2.3. Statistical Methods. Descriptive statistical methods were
used to analyze demographic characteristics, and differences
between groups were calculated using Student’s 𝑡-test for
independent samples or Fisher’s exact test, where appropriate.
Statistical significance was established at 𝑃 < 0.05. Data were
analyzed using an SPSS statistical package (SPSS Statistics
15.0, SPSS Inc., Armonk, NY).
3. Results
3.1. Patient Characteristics. We found 14 patientsmeeting our
search criteria. Rhizopus was identified as the genus in all
cases. The demographic characteristics of the patients are
reported in Table 1. The mean age of the patients was 39.9
+/− 20.3 years (range 5–65 years), with men presenting the
majority (64.3%). The most common underlying disease was
DM (71.4%), followed by hematological malignancy (42.8%)
and chronic renal insufficiency on hemodialysis (21.4%). All
patients with chronic renal insufficiency were diabetic. Five
patients with hematological malignancy had ALL and only
one had acute myelocytic leukemia; they had all received
chemotherapy, including steroids, and two were neutropenic
on diagnosis. Of the diabetic patients, 4 presented with dia-
betic ketoacidosis. Hypertension was a common comorbidity
(50%). Three of the patients were children, all with ALL.
3.2. Presentation. Presenting signs and symptoms are
reported in Table 2. Fever (71.4%) and rhinorrhea (57.1%)
were the most common signs. Patients also complained
of headache, ocular pain, facial edema, and when ocular
involvement was present, visual abnormalities.
3.3. Sites of Infection and Treatment. All patients had rhino-
cerebral involvement (Figure 1). On presentation, 4 patients
had overt orbital involvement. All patients received medical
treatment with conventional (deoxycholate) amphotericin B
at 1–1.5mg/kg body weight/day within 24 hours of admis-
sion. Amphotericin B was administered through a central
line, with a median duration of treatment of 11.5 days.
Medical treatment was initiated empirically in 10 patients
and after microbiological identification in the remaining
cases. Hypokalemia and creatinine elevations appeared in
6 patients after treatment, but these alterations did not
ultimately require switching or modifying therapy. Surgery
was performed in 11 (78.6%) of cases (Figure 1). We did not
identify cases of disseminated MCM.
3.4. Outcome. In-hospital mortality was 50%. Mean hospital
stay was 19.5 days (range: 1–79 days). The stratified character-
istics of survivors and nonsurvivors are reported in Table 1.
Nonsurvivors were older and more likely to be diabetic.
All of the patients that presented with diabetic ketoacidosis
died, and all nonsurvivors underwent surgery. Some rou-
tine laboratory tests on admission were also analyzed. No
differences were found in hemoglobin, white blood count,
or serum electrolytes (data not shown) between survivors
and nonsurvivors. Mean creatinine was 3.68 +/− 3.15mg/dL
in nonsurvivors and 1.69 +/− 1.15mg/dL in survivors, with
no statistical difference between groups. Serum albumin
levels were significantly lower on admission in nonsurvivors
(2.3 +/− 0.23 g/dL) in comparison with survivors (3.15 +/−
0.46 g/dL), with a 𝑃 = 0.03. There was no difference in
the time of initiation of treatment between survivors and
nonsurvivors (data not shown).
4. Discussion
The majority of the patients in our series were male, a
trend that has been consistently reported in case series from
different countries [10–12]. The most common underlying
disease in our series was DM.DM is associated with impaired
neutrophil function, microvascular insufficiency, and in the
case of ketoacidosis, other metabolic abnormalities that
promote fungal growth [11–13]. Rhizopus species have an
active ketone reductase system and thrive in high glucose
and acidotic conditions. These patients also have decreased
phagocytic activity because of impaired glutathione path-
way. Normal serum inhibits Rhizopus whereas serum of
the diabetic ketoacidosis patients stimulates its growth [14].
Notably, in our series, 4 patients presented with diabetic
ketoacidosis. In a series of 28 MCM cases, 64% cases had
DM and 55.6% of those cases had diabetic ketoacidosis [15], a
proportion similar to our findings. However, in other series,
complications associated with DM accounted for only 17%
of cases of MCM [16]. Chronic renal insufficiency is another
condition that predisposes to MCM infection. In our series,
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Table 1: Demographic data.
Total (%) Survivors (%) Nonsurvivors (%) 𝑃
Patients 14 (100) 7 (100) 7 (100)
Female 5 (35.7) 2 (28.6) 3 (57.1) 0.4
Male 9 (64.3) 5 (71.4) 4 (57.1) 0.5
Age (years) 39.9 27.4 52.4 0.03∗
DM 10 (71.4) 3 (42.8) 7 (100) 0.03∗
HM 6 (42.8) 4 (57.1) 2 (28.6) 0.29
CRI 3 (21.4) 0 (0) 3 (42.8) 0.09
KET 4 (28.6) 0 (0) 4 (57.1) 0.03∗
Hypertension 7 (50) 2 (28.6) 5 (71.4) 0.14
Surgery 11 (78.6) 4 (57.1) 7 (100) 0.09
CRI: chronic renal insufficiency; DM: diabetes mellitus; HM: hematological malignancy; KET: diabetic ketoacidosis. Significant 𝑃 values are indicated in bold.
𝑃 ≤ 0.05.
(a) (b)
Figure 1: (a) An example of a computed tomography showing sinusitis (black arrows). Biopsies were positive formucormycosis in this patient.
(b) Postsurgical magnetic resonance image (T1 weighted) in a patient with ocular involvement. The patient recovered well.
Table 2: Presenting signs and symptoms.
Sign/symptom 𝑛 (%)
Fever 10 (71.4)
Rhinorrhea 8 (57.1)
Cephalea 7 (50)
Ocular pain 4 (28.6)
Vision loss 3 (21.4)
Palpebral edema 3 (21.4)
Facial edema 2 (14.3)
Proptosis 1 (7.1)
patients with renal disease all had concomitant DM and were
on hemodialysis. In a 1997 case series with patients from our
institution, rhinocerebral MCMwas diagnosed in 22 patients
over 15 years [17]. Twenty of these patients were diabetic,
and half presented with ketoacidosis. In contrast with our
study, hematologic malignancy was uncommon, with only
one patient presenting with myelodysplastic syndrome [17].
This could indicate increasing number of patients with
hematological malignancies admitted to our institution, the
use of more aggressive immunosuppressive regimens in these
patients, and improved control of DM complications in our
population. These trends have been recognized in other
studies as well [12, 16].
In the largest case series, patients with hematological
malignancies (mainly acute leukemia) represent the group
with the highest prevalence and with rapidly increasing rates
of MCM [12, 16]. In our series 6 of our patients had hema-
tological malignancies, and in all cases these were acute
leukemia (ALL and AML). Although neutropenia has also
been hailed as an important factor in the development of
MCM, only 2 of our patients withALL presentedwith neutro-
penia.
MCM infection may have a rhinocerebral, rhinoorbital,
pulmonary and soft-tissue extension, among others. More-
over, it can also present as a devastating disseminated form.
All cases in our series had rhinocerebral or rhinoorbital
involvement. Recent registries have reported conflicting data
about the most common site of infection. In a global registry,
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the lung (58.5%) was the main site of infection, followed
by rhinocerebral or rhinoorbital involvement (19.5%) [16].
In an Italian series, rhino-orbital-cerebral involvement was
the most common site of infection (35%), followed by the
lung (25%) [18]. Interestingly, we found no evidence of lung
involvement or of disseminated disease in our series.
The most common signs and symptoms were fever,
rhinorrhea, and headache, while the most ominous symptom
was vision loss. Despite aggressivemedical and surgical treat-
ment, in-hospital mortality in our patients was 50%, which is
similar to rates reported in other case series [16]. Although it
is higher than the rate reported in a recent population-wide
study (22%) [4], our series is quite different in terms of infec-
tion site (mainly rhinocerebral) and treatment (conventional
amphotericin B). All of our patients received conventional (as
opposed to liposomal) amphotericin B at doses that ranged
from 1 to 1.5mg/kg/day. Although surgical therapy has been
associated with improved outcome in some studies [5, 6],
all of the nonsurvivors in our study underwent surgical
treatment.This could be explained by clinically milder forms
of MCM infection in those patients that did not have to
undergo surgery.
Notwithstanding our small sample, we could identify
factors that were significantly different in nonsurvivors when
compared with survivors: these were older age, DM, and
ketoacidosis at presentation. Ketoacidosis represents a severe
complication of DM in its own right and indicates poor
glycemic control, so along with old age it is not surprising
that it would be associated with worse outcomes. Of note,
all of the patients with chronic renal failure died as well.
This accounts for the higher creatinine levels (although not
significant) on admission in nonsurvivors. Serum albumin
on admission was lower in nonsurvivors as well, which
could indicate malnutrition, another predisposing factor for
immunosuppression.
5. Conclusion
In conclusion, MCM is a life-threatening infection that most
commonly affects immunocompromised individuals and that
despite aggressive multimodal treatment carries a significant
risk of mortality. A high index of suspicion is required in
order to begin the appropriate diagnostic workup and treat-
ment. Our cases most commonly involved the rhino-orbital-
cerebral cavities, and the main underlying disease was
DM. Unfortunately, due to economic limitations, the use
of liposomal amphotericin B in third world countries is
often prohibitive, and our patients were instead treated with
conventional amphotericin B. Fortunately, there were no
cases in our series where side effects (such as renal injury
or hypokalemia) forced a change in therapy. In light of
evidence suggesting that early and aggressive use of liposomal
amphotericin B could improve outcomes [18], this issue
should be evaluated thoroughly.
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